Lineweaver Wealth Advisors LLC Invests $448,000 in Agilent Technologies, Inc. $A

Key Points

• Lineweaver Wealth Advisors LLC has acquired a new stake in Agilent Technologies, purchasing 3,795 shares valued at around $448,000 during the second quarter of 2023.
• Agilent Technologies reported earnings of $1.37 EPS for its most recent quarter, meeting analyst expectations and showing a 10.1% increase in revenue year-over-year to $1.74 billion.
• Wall Street analysts have mixed ratings on Agilent Technologies, with a consensus target price of $140.08, reflecting an overall "Moderate Buy" rating from several investment firms.

Lineweaver Wealth Advisors LLC acquired a new position in Agilent Technologies, Inc. (NYSE:A - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 3,795 shares of the medical research company's stock, valued at approximately $448,000.

Several other institutional investors and hedge funds have also made changes to their positions in A. Brighton Jones LLC boosted its position in shares of Agilent Technologies by 6.1% in the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock worth $626,000 after buying an additional 270 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Agilent Technologies by 4.9% during the 4th quarter. Royal Bank of Canada now owns 834,041 shares of the medical research company's stock worth $112,045,000 after acquiring an additional 39,321 shares during the period. Toronto Dominion Bank lifted its holdings in shares of Agilent Technologies by 5.8% during the 4th quarter. Toronto Dominion Bank now owns 153,898 shares of the medical research company's stock worth $20,674,000 after acquiring an additional 8,420 shares during the period. Tidal Investments LLC increased its position in Agilent Technologies by 8.9% during the 4th quarter. Tidal Investments LLC now owns 16,058 shares of the medical research company's stock worth $2,157,000 after purchasing an additional 1,306 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in Agilent Technologies by 380.5% during the 4th quarter. Two Sigma Advisers LP now owns 504,000 shares of the medical research company's stock worth $67,707,000 after purchasing an additional 399,100 shares in the last quarter. 87.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Robert W. Baird increased their target price on shares of Agilent Technologies from $141.00 to $142.00 and gave the stock an "outperform" rating in a research report on Thursday, August 28th. Evercore ISI lowered their price objective on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating for the company in a research report on Thursday, August 28th. Wells Fargo & Company increased their price objective on shares of Agilent Technologies from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Monday. Barclays reaffirmed an "equal weight" rating and issued a $125.00 price objective on shares of Agilent Technologies in a research report on Friday, August 29th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research report on Thursday, May 29th. Six research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Agilent Technologies presently has a consensus rating of "Moderate Buy" and a consensus target price of $140.08.

Agilent Technologies Stock Performance

Shares of NYSE A traded down $1.38 during midday trading on Friday, reaching $126.24. 2,844,312 shares of the company traded hands, compared to its average volume of 1,952,423. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The stock has a 50-day moving average price of $120.19 and a 200 day moving average price of $115.94. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84. The company has a market cap of $35.79 billion, a price-to-earnings ratio of 29.63, a PEG ratio of 3.94 and a beta of 1.24.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting analysts' consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.67 billion. During the same quarter last year, the business posted $1.32 EPS. Agilent Technologies's revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th will be given a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.8%. Agilent Technologies's dividend payout ratio (DPR) is currently 23.24%.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the company's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the sale, the chief executive officer directly owned 37,448 shares in the company, valued at $4,397,893.12. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.